Danshen-Chuanxiongqin Injection attenuates cerebral ischemic stroke by inhibiting neuroinflammation via the TLR2/ TLR4-MyD88-NF-κB Pathway in tMCAO mice.
10.1016/S1875-5364(21)60083-3
- Author:
Xiao-Jing XU
1
;
Jin-Bo LONG
1
;
Kai-Yu JIN
1
;
Li-Bing CHEN
1
;
Xiao-Yan LU
2
;
Xiao-Hui FAN
3
,
4
Author Information
1. Pharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
2. Pharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China. Electronic address: luxy@zju.edu.cn.
3. Pharmaceutical Informatics Institute, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China
4. State Key Laboratory of Component-Based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China. Electronic address: fanxh@zju.edu.cn.
- Publication Type:Journal Article
- Keywords:
Cerebral ischemic stroke;
Choroid plexus;
Danshen-Chuanxiongqin Injection;
Network pharmacology;
Neuroinflammation;
Neutrophil
- MeSH:
Brain Ischemia/genetics*;
Drugs, Chinese Herbal;
Humans;
Infarction, Middle Cerebral Artery/genetics*;
Ischemic Stroke;
Myeloid Differentiation Factor 88/genetics*;
NF-kappa B/metabolism*;
Stroke/genetics*;
Toll-Like Receptor 2;
Toll-Like Receptor 4/metabolism*
- From:
Chinese Journal of Natural Medicines (English Ed.)
2021;19(10):772-783
- CountryChina
- Language:English
-
Abstract:
Danshen-Chuanxiongqin Injection (DCI) is a commonly used traditional Chinese medicine for the treatment of cerebral ischemic stroke in China. However, its underlying mechanisms remain completely understood. The current study was designed to explore the protective mechanisms of DCI against cerebral ischemic stroke through integrating whole-transcriptome sequencing coupled with network pharmacology analysis. First, using a mouse model of cerebral ischemic stroke by transient middle cerebral artery occlusion (tMCAO), we found that DCI (4.10 mL·kg
